| |
Glycosmedia
- weekly publication |
| |
Due to lack of funding Glycosmedia will now
be published weekly. If we can raise sufficient income we will
revert back to a daily publication. We would welcome offers of
advertising, sponsorship or educational grants. Please contact
us for information (Editor) |
| |
|
 |
2009
Annual Evidence Update on Diabetic Retinopathy |
| |
The update of the Annual Evidence Update on
Diabetic Retinopathy provides an opportunity to present an up-to-date
comprehensive collection of information that has been subject to
rigorous selection criteria (NHS Evidence, UK) |
| |
|
|
Incretin-based
therapies: new treatments for type 2 diabetes in the new millennium |
| |
The low risk of hypoglycemia, and beneficial
or neutral effects on body weight, render GLP-1 agonists and DPP-4
inhibitors suitable alternatives to insulin secretagogues and insulin
in overweight and elderly patients (Dovepress) |
| |
|
|
Folic
acid supplementation normalizes the endothelial progenitor cell
transcriptome of patients with type 1 diabetes |
| |
Signaling pathways modulated by folic acid may
be potential therapeutic targets to improve endothelial progenitor
cell function (Cardiovascular Diabetology) |
| |
|
|
National
Inpatient Audit Day |
| |
This note is to inform you of the aims of the
audit and to encourage you to start planning in advance with your
team so you will be able to participate (Young Diabetologists,
UK) |
| |
|
|
Liraglutide
vs insulin glargine and placebo in combination with metformin
and sulfonylurea therapy in type 2 diabetes mellitus |
| |
Liraglutide added to metformin and sulfonylurea
produced significant improvement in glycaemic control and bodyweight
compared with placebo and insulin glargine. The difference vs insulin
glargine in HbA1c was within the predefined non-inferiority margin
(Diabetologia) |
| |
|
|
Is
type 1 diabetes seasonal? |
| |
The results from this large, well-conducted
study confirm what has been seen in previous small studies. However,
any interpretation of these findings should take into account several
shortcomings that the researchers themselves raise (NHS Choices,
UK) |
| |
|
|
Epocal
Announces FDA Clearance of Glucose Test |
| |
The FDA clearance of glucose represents one
of many milestones to come for Epocal and for healthcare as we
continue to expand the test menu of the first wireless and cost
effective point of care testing system (San Francisco Business
Times, USA) |
| |
|
|
Alcohol
consumption and diabetes risk in the Diabetes Prevention Program |
| |
Despite overall low rates of alcohol consumption,
there was a reduced risk of incident diabetes in those who reported
modest daily alcohol intake and were assigned to metformin or lifestyle
modification. Moderate daily alcohol intake is associated with
lower insulin secretion—an effect that warrants further investigation (American Journal of Clinical Nutrition) |
| |
|
|
Dwayne
Johnson, Novo Nordisk and the Entertainment Industry Foundation
Educate Families about Healthy Living and Diabetes |
| |
Johnson Asks Families to be Diabetes Aware in
New Public Service Announcement (PharmaLive) |
| |
|
|
PRESENT
Diabetes |
| |
An innovative educational concept for the diabetes
management team. It is designed to unite researchers and care givers
around the world into a collaborative community, with the single
goal of fighting the epidemic that diabetes has become (PRESENT
Diabetes) |
| |
|
|
The
polymorphisms of UCP2 and UCP3 genes associated with fat metabolism,
obesity and diabetes |
| |
This review summarizes data supporting the roles
of UCP2 and UCP3 in energy dissipation, as well as the genetic
variety association with fat metabolism, obesity and diabetes in
humans (Obesity Reviews) |
| |
|
|
Hepatic
Insulin Sensitivity Assessed by Integrated Model of Hepatic and
Peripheral Glucose Regulation |
| |
Because insulin resistance in liver and peripheral
tissue may play a differential role in the pathogenesis of diabetes,
this analysis can serve as a simple one-step approach to obtain
metabolic indexes specific to EGP suppression and stimulating glucose
uptake (Diabetes Technology & Therapeutics) |
| |
|
|
Diamyd
to include children and accelerate patient recruitment in US
Phase III study with the Diamyd® diabetes vaccine |
| |
Diamyd Medical reported today that from September
1, children from 10 years ofage with type 1 diabetes will be included
in the company's US Phase III study of the Diamyd® diabetes vaccine. The company is also trebling the number of clinics and is
investing in expanded recruitment activities in the US (Diamyd
Medical) |
| |
|
